Thalassaemia – Diagnostics – Overview of Information and Clinical Research

Thalassaemia diagnostics involve a series of blood tests and genetic screening methods that help doctors identify this inherited blood disorder and determine its type and severity. Understanding when and how to get tested is essential, especially for people with family histories of the condition or those from regions where thalassaemia is more common.

Introduction: Who Should Seek Diagnostic Testing

Diagnostic testing for thalassaemia is most important for specific groups of people, though anyone experiencing symptoms of anemia should consider speaking with their healthcare provider. People who should undergo testing include those who come from families where thalassaemia runs through generations, as this is an inherited blood disorder passed from parents to children through genes^[1]. The condition is particularly common among individuals with ancestral connections to parts of the world where malaria has been prevalent, including Africa, Southern Europe, the Middle East, and West, South, and East Asia^[1].

Testing becomes especially advisable when children show symptoms during their first two years of life. Parents should seek medical attention if their child experiences persistent tiredness, weakness, pale skin, or yellowing of the skin and eyes^[2]. Children born with more severe forms of thalassaemia are usually healthy at birth, but disease signs typically begin to appear after the first six months when the body transitions from fetal hemoglobin to adult hemoglobin production^[4].

People who experience common anemia symptoms should also consider diagnostic testing. These symptoms include feeling unusually tired, having trouble breathing during normal activities, feeling cold frequently, experiencing dizziness, and noticing that their skin appears paler than usual^[1]. Additional warning signs can include having a fast heartbeat, regular headaches, leg cramps, and difficulty concentrating^[3].

⚠️ Important

Couples planning to have children should strongly consider getting tested for their thalassaemia carrier status before starting a family, especially if they have ancestry from regions where the condition is common. Both partners being carriers increases the risk of having a child with thalassaemia major, the most severe form of the disease that requires lifelong treatment^[9].

Classic Diagnostic Methods

The diagnostic process for thalassaemia begins with a physical examination performed by a healthcare provider. During this examination, the doctor will look for physical signs of the condition, including checking for an enlarged spleen, which is a common finding in people with thalassaemia^[5]. The spleen often becomes enlarged because it works harder to filter out the abnormal red blood cells that the body produces when someone has this blood disorder.

Blood tests are the primary method for diagnosing thalassaemia. A complete blood count, commonly abbreviated as CBC, is typically the first test ordered. This test measures the number of red blood cells in your blood and can reveal anemia. When the blood sample is examined under a microscope, red blood cells from someone with thalassaemia appear smaller than normal and have an abnormal, irregular shape^[5]. These characteristics help distinguish thalassaemia from other types of anemia.

A specialized test called hemoglobin electrophoresis is crucial for confirming the diagnosis and identifying the type of thalassaemia. This test can detect the presence of abnormal forms of hemoglobin and is particularly effective at identifying beta thalassaemia^[5]. Hemoglobin is the protein in red blood cells that carries oxygen throughout the body, and in thalassaemia, this protein is either abnormal or produced in insufficient amounts.

For detecting alpha thalassaemia, doctors use a different approach called mutational analysis or genetic testing. This test examines the specific genes responsible for producing alpha globin chains, which are building blocks of hemoglobin^[5]. Because alpha thalassaemia results from genes being deleted or missing rather than just altered, this DNA-based testing is more reliable for this particular type.

The severity of thalassaemia depends on how many genes are affected. For alpha thalassaemia, there are four genes involved, two inherited from each parent. Diagnostic tests determine how many of these genes are defective or missing. One defective gene usually causes no symptoms and is called alpha thalassaemia minima. Two defective genes result in mild symptoms, known as alpha thalassaemia minor. Three defective genes cause moderate to severe symptoms, called Hemoglobin H disease. Four defective genes is the most severe form and is usually fatal^[1].

For beta thalassaemia, only two genes are involved, one from each parent. Diagnostic testing reveals whether a person has inherited one altered gene, making them a carrier with thalassaemia minor, or two altered genes, resulting in thalassaemia major, also known as Cooley’s anemia. People with thalassaemia minor may not have any symptoms or only experience mild anemia, while those with thalassaemia major develop severe symptoms requiring lifelong treatment^[4].

Testing can identify carriers of thalassaemia who may not have symptoms themselves but can pass the condition to their children. A carrier typically has one faulty gene but remains healthy because the other gene produces enough hemoglobin. Carriers have smaller red blood cells than usual and may have slightly lower hemoglobin levels, but this is not the same as iron deficiency anemia and does not require treatment^[6].

Prenatal and Newborn Screening

Testing for thalassaemia can be performed before a baby is born if there is concern that the child might inherit the condition. Two main prenatal tests are available for expectant parents. Chorionic villus sampling involves removing a tiny piece of the placenta, the organ that provides oxygen and nutrients to the baby during pregnancy. This tissue sample is then analyzed in a laboratory to check for thalassaemia genes. The procedure is typically performed around the eleventh week of pregnancy^[10].

The second option is amniocentesis, which checks a sample of the fluid surrounding the unborn baby in the womb. This test can determine not only if the baby has thalassaemia but also how severe the condition might be. Amniocentesis is usually conducted around the sixteenth week of pregnancy^[10]. Both prenatal tests allow parents to know in advance if their child will have thalassaemia and prepare for the specialized care that may be needed.

In England, screening for thalassaemia during pregnancy is offered to all pregnant women to assess whether there is a risk of their child being born with the condition. Some types of thalassaemia may also be detected during the newborn blood spot test, commonly known as the heel prick test, which is performed shortly after birth^[6]. Most children with moderate to severe thalassaemia show clear symptoms within their first two years of life, prompting further diagnostic testing^[10].

Diagnostics for Clinical Trial Qualification

When patients consider participating in clinical trials for new thalassaemia treatments, they must undergo additional diagnostic testing to determine if they qualify for the study. Clinical trials typically require comprehensive blood testing to confirm the specific type and severity of thalassaemia. This includes the same basic diagnostic tests used for initial diagnosis, such as complete blood counts and hemoglobin electrophoresis, but the results must meet specific criteria defined by the research protocol.

Genetic testing plays an essential role in qualifying patients for clinical trials, particularly those investigating gene therapy approaches. In early 2024, a new cell-based gene therapy called CASGEVY was approved for treating transfusion-dependent beta thalassaemia in patients twelve years and older. This therapy requires extensive genetic analysis to confirm the patient has the appropriate type of beta thalassaemia that would respond to treatment^[12]. The diagnostic process includes detailed DNA sequencing to identify the specific genetic mutations responsible for the patient’s condition.

Clinical trials often require evidence of transfusion dependency, meaning patients must have documentation showing how frequently they receive blood transfusions. This information helps researchers determine if experimental treatments might reduce or eliminate the need for regular transfusions. Patients typically need medical records showing their transfusion history over several months or years before being accepted into a trial.

Assessment of organ function is another critical component of diagnostic testing for clinical trial qualification. Because thalassaemia and its treatments can affect various organs, particularly the heart and liver, trial protocols usually require testing to measure how well these organs are working. Blood tests checking liver function, heart monitoring through electrocardiograms, and imaging studies may all be necessary to ensure patients can safely participate in the experimental treatment being studied.

⚠️ Important

Iron overload measurements are particularly important for clinical trial qualification. Regular blood transfusions cause iron to build up in the body, and excess iron levels can damage vital organs. Trials often measure serum ferritin levels in the blood to assess iron overload and may require specialized imaging to check iron deposits in the liver and heart^[16]. These tests help researchers select appropriate participants and monitor treatment safety during the study.

Age requirements and overall health status also factor into clinical trial diagnostics. Some trials focus on specific age groups, such as pediatric patients or adults, while others may exclude patients with certain complications from thalassaemia. Comprehensive medical histories and physical examinations help determine if potential participants meet all eligibility criteria. Patients interested in clinical trials should discuss their diagnostic test results with their healthcare team to understand which studies might be appropriate for their specific situation.

Prognosis and Survival Rate

Prognosis

The outlook for people with thalassaemia has improved dramatically over recent decades due to advances in treatment. People with thalassaemia trait or minor forms typically have a normal lifespan and may experience only mild anemia or no symptoms at all, with many not requiring any specific treatment^[5]. These individuals can live completely normal lives without the condition affecting their daily activities or overall health.

For those with more severe forms like thalassaemia major, the prognosis depends heavily on receiving appropriate and consistent treatment. With current therapies including regular blood transfusions and chelation therapy to remove excess iron from the body, outcomes have improved significantly. Patients whose care is coordinated by specialized thalassaemia centers tend to have much better outcomes than those treated in programs without specialized expertise^[16]. The prognosis is best when treatment begins early, transfusions maintain adequate hemoglobin levels, and iron chelation therapy is followed consistently to prevent organ damage.

Several factors influence disease progression and outcomes. The most critical is adherence to the prescribed treatment schedule, particularly maintaining regular blood transfusions and chelation therapy to prevent iron overload. Iron buildup in organs, especially the heart and liver, represents one of the most serious complications and can be life-threatening if not properly managed^[5]. Patients who develop complications such as heart problems, liver disease, or endocrine disorders may face more challenging health outcomes, though many of these complications can be prevented or managed with proper monitoring and treatment.

Bone marrow or stem cell transplantation offers the only potential cure for thalassaemia, though this treatment carries significant risks including graft versus host disease, where the transplanted cells attack the patient’s body. The procedure is not performed frequently because the risks must be carefully weighed against the long-term benefits^[13]. Recent approval of gene therapy options like CASGEVY provides new hope for patients with transfusion-dependent beta thalassaemia, potentially offering an alternative path to independence from regular transfusions^[12].

Survival Rate

In the past, severe thalassaemia was often fatal by early adulthood, with patients rarely surviving beyond their twenties or thirties. However, modern treatment approaches have transformed survival rates dramatically. Today, people with severe thalassaemia who receive proper treatment are likely to live into their fifties, sixties, and beyond^[6]. This remarkable improvement reflects advances in blood screening that reduced transfusion-related infections, better iron chelation treatments that are easier to take, and improved management of complications.

Without adequate treatment, severe thalassaemia can lead to early death, typically between ages twenty and thirty, primarily due to heart failure and liver problems caused by iron overload^[5]. Regular blood transfusions and effective chelation therapy to control iron levels have been shown to significantly improve survival outcomes and help prevent these life-threatening complications. Survival and quality of life continue to improve as new treatments become available and more patients gain access to specialized care centers with experience managing this complex condition^[22].

The 2021 Global Burden of Disease Survey found that approximately 1.31 million people worldwide have severe thalassaemia, causing about 11,100 deaths annually^[7]. Survival rates vary considerably depending on geographic location and access to quality healthcare services, with patients in high-resource settings generally experiencing better outcomes than those in regions with limited medical infrastructure. The condition affects males and females nearly equally, with only slightly higher prevalence in males^[7].

#1 Clinical Trials Search in Europe